The effect of peripherally inserted central catheter (PICC) valve technology on catheter occlusion rates--the 'ELeCTRiC' study

J Vasc Access. 2012 Oct-Dec;13(4):421-5. doi: 10.5301/jva.5000071.

Abstract

Purpose: Peripherally Inserted Central Catheters (PICCs) are increasingly being used to provide short to medium-term central venous access. The current study was designed to test the hypothesis that PICC valve technology does not influence PICC occlusion rates.

Methods: Intensive care unit (ICU) patients who required a PICC were randomized to one of three types of dual lumen PICC (open ended non-valved, Groshong valve, PASV valve). PICC occlusions were recorded and managed with a protocol that used urokinase.

Results: A total of 102 patients were recruited to the study. The overall risk of occlusion per catheter was 35% (95% CI 26% to 44%). The overall rate of occlusion was 76 occlusions per 1000 catheter days (95% CI 61 to 95). Presence or type of valve did not significantly influence this rate (open-ended non-valved PICC 38% of catheters, 79 occlusions per 1000 catheter days; Groshong 38% of catheters, 60 occlusions per 1000 catheter days; PASV 27% of catheters, 99 occlusions per 1000 catheter days). The dose of urokinase required to treat PICC occlusions did not significantly differ between PICC types.

Conclusions: Valved PICCs do not appear to influence PICC occlusion rates.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Catheter Obstruction / etiology*
  • Catheterization, Central Venous / adverse effects
  • Catheterization, Central Venous / instrumentation*
  • Catheterization, Peripheral / adverse effects
  • Catheterization, Peripheral / instrumentation*
  • Central Venous Catheters*
  • Early Termination of Clinical Trials
  • England
  • Equipment Design
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Intensive Care Units
  • Male
  • Middle Aged
  • Risk Factors
  • Thrombolytic Therapy / methods
  • Treatment Outcome
  • Upper Extremity Deep Vein Thrombosis / diagnosis
  • Upper Extremity Deep Vein Thrombosis / drug therapy
  • Upper Extremity Deep Vein Thrombosis / etiology*
  • Urokinase-Type Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator